Develops therapies for patients with severe and rare diseases, including complement-related and iron-overload disorders.
10-K for FY2025, filed Mar 16, 2026We are a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and…View ↗
Partners pay for licenses, related know-how, research and development work, and participation in joint research or development committees. Payments may include upfront fees, milestone payments, and royalties tied to product sales.
10-K for FY2025, filed Mar 16, 2026The Company evaluates the promised goods or services in these agreements to determine which ones represent distinct performance…View ↗
$858K
10-K for FY2025, filed Mar 16, 2026
$858K ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
License
Licensed
10-K for FY2025, filed Mar 16, 2026 |
93% |
License, FY2025
$800K Sources
|
Licensed |
|
Collaboration and license revenue
Licensed
10-K for FY2025, filed Mar 16, 2026 |
100% |
Collaboration and license revenue, FY2025
$858K Sources
|
Licensed |
Drug-development partners work with Rallybio directly on discovery and development; agreements may include licenses, research services, and joint research or development committees.
10-K for FY2025, filed Mar 16, 2026
No. It lost $9M in FY2025.
10-Q for Q3 FY2026, filed Oct 27, 2026
−$2.7MView ↗
8-K, filed Nov 12, 2026
The Company also announced updates about its previously announced special cash distribution of $13.90 per share (the “Cash Distribution”).…View ↗
8-K, filed Nov 6, 2026
Rallybio Corporation (the “Company”) previously disclosed that, subject to the satisfaction or waiver of any outstanding closing…View ↗
8-K, filed Jun 1, 2026
On May 31, 2026, Rallybio Corporation, a Delaware corporation (“Rallybio”), entered into an Agreement and Plan of Merger and Reorganization…View ↗
8-K, filed May 4, 2026
On May 3, 2026, Candid terminated the Merger Agreement concurrently with entering into a Permitted Alternative Agreement (as defined in the…View ↗
Portfolio exits
The earlier report included maternal-fetal and metabolic disease programs; the latest report says Rallybio discontinued its maternal-fetal program and sold its interest in a metabolic-disease program, while continuing work on complement and hematology programs.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Mar 16, 2026In April 2025, we announced the discontinuation of our RLYB212 program for the prevention of FNAIT based on PK data from the Phase 2…View ↗
In July 2019, we formed a joint venture with Exscientia Limited ("Exscientia"), an Oxford, UK-based artificial intelligence ("AI") and…View ↗
We are a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and…View ↗
Proposed strategic combination
The earlier report described a rare-disease drug pipeline; the latest report proposes a merger with Candid, which is advancing T-cell engager therapies for autoimmune diseases, while Rallybio plans to reduce administrative operations.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Mar 16, 2026We are a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for…View ↗
Loading...